Clinical Risk-Reward Conversation
Compare treatment risk with the risk of leaving the condition untreated
- Difficulty
- Moderate
- Time to result
- ~days to results
- Steps
- 5
- Confidence
- 91%
Moore frames medical choice as a comparison between competing risks rather than a search for a cost-free option. First, define the likely harm of the untreated condition; her example contrasts possible semaglutide harms with the long-term consequences she associates with severe psoriatic arthritis. Next, distinguish known evidence from uncertain inference. In the microdosing discussion, she extrapolates potential adverse effects from standard high-dose data while acknowledging that long-term microdosing studies are lacking. Patient-specific susceptibility, reasonable alternatives, and the expected benefit then shape the balance. Finally, the clinician explains the uncertainty, the patient chooses through informed consent, and both agree on close monitoring and review. The framework improves the decision conversation, but it does not prove Moore's medical conclusions or turn lower dose into zero risk.
Origin
Extracted from The Diary of a CEO
Core principles
- 01Compare an intervention with realistic alternatives, not with zero risk
- 02Separate established evidence from extrapolation and clinical hypothesis
- 03Match risk to the patient's susceptibility and untreated condition
- 04Let the informed patient participate in the decision
- 05Monitor after the decision because the balance can change
How to run it
- 1
Define the untreated risk
Describe what may happen if the condition remains untreated or current care continues. Use evidence appropriate to the individual rather than assuming that no intervention means no harm.
Pro tip State the relevant time horizon for each risk.
Watch out Do not exaggerate disease progression to make treatment appear safer.
- 2
Map benefits, harms, and gaps
Separate established benefits and adverse effects from observational findings, anecdotes, mechanistic theories, and unanswered questions. Include dose and population differences.
Pro tip Label each important claim by evidence type during the discussion.
Watch out Absence of a detected safety signal is not proof of long-term safety.
- 3
Personalize the comparison
Consider the patient's age, conditions, medications, frailty, goals, and susceptibility to both treatment harms and untreated disease. Compare other viable options as well.
Pro tip Ask which outcome the patient most wants to avoid.
- 4
Share the uncertainty
Explain the mechanism and evidence in understandable language without presenting a hypothesis as settled fact. Invite questions and verify that the patient understands the trade-off.
Pro tip Ask the patient to explain the choice back in their own words.
Watch out A persuasive explanation is not informed consent if material uncertainty is omitted.
- 5
Decide and monitor
Record the informed choice, the expected outcomes, warning signs, and the next review. Revisit the balance when symptoms, evidence, or circumstances change.
Pro tip Predefine what would trigger continuation, adjustment, or stopping.
Watch out Urgent symptoms require timely medical care rather than waiting for a routine review.
In the wild
Moore says she compared the possible risks she saw in high-dose GLP-1 data with what she believed were the long-term risks of her severe psoriatic arthritis, including chronic pain, impaired movement, and spinal damage. She concluded that a clinician-managed small dose had a favourable balance for her. This is her personal reasoning, not a general safety finding.
→ The decision considered both treatment risk and untreated illness rather than evaluating the drug in isolation.
Illustrative example: a clinician explains that a proposed treatment has evidence for one indication but uncertain benefit for the patient's off-label goal. They compare non-treatment, standard care, and the proposed option; identify known adverse effects and evidence gaps; and agree on measurable outcomes and stopping rules before the patient decides.
→ The patient makes a documented choice with uncertainty and alternatives visible.
Common mistakes
Comparing treatment with zero risk
Untreated disease and alternative treatments also have consequences. Excluding them distorts the decision.
Presenting extrapolation as evidence
The guest explicitly extrapolates microdose harms from higher-dose data because long-term microdosing evidence is incomplete. That uncertainty must remain visible.
Treating consent as a one-time signature
Monitoring and review are part of the decision because new symptoms or evidence can change the risk-reward balance.
Is it for you?
Best for
It is best for clinician-patient decisions where both the intervention and non-treatment carry meaningful risk.
Not ideal for
It is not a scoring tool that can establish safety or replace specialist guidance, high-quality evidence, or emergency care.
From the transcript
“We have to think about the risk-reward ratio.”
“It comes down to understanding the mechanism of action of how these things work”
“sharing that as best as you can with your patients and then having a conversation and letting the patient decide.”
From the episode
The Ozempic Expert: Ozempic Transforms Your Gut Microbiome! People Are Being Overdosed On Ozempic! Microdosing Saved My Life! - Dr Tyna Moore